Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United Kingdom

Epidemiology and Infection

Volumn 136, Issue 6, 2008, Pages 800-812

  McVernon, J ^a,b,c   Ramsay, M E ^b   McLean, A R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ADOLESCENT; AGE DETERMINATION; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; CHILD; CONTROLLED STUDY; DISEASE CONTROL; DISEASE DURATION; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNITY; IMMUNIZATION; INFANT; INFECTION SENSITIVITY; MATHEMATICAL MODEL; PROTECTION; RISK FACTOR; STRATEGIC PLANNING; TREATMENT DURATION; UNITED KINGDOM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION; GREAT BRITAIN; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HOST-PATHOGEN INTERACTIONS; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; MODELS, THEORETICAL; VACCINES, CONJUGATE;

EID: 42149117424     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807009168     Document Type: Article

References (57)

1. O'Brien H. Hib immunisation catch up programme in North East Thames. CDR Review 1994; 4: R17-18.
2. Heath P, et al. Antibody concentration and clinical protection after Hib conjugate vacination in the United Kingdom. Journal of the American Medical Association 2000; 284: 2334-2340.
3. McVernon J, et al. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361: 1521-1523.
4. Trotter C, Ramsay M, Slack M. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up immunisation campaign. Communicable Disease and Public Health 2003; 6: 55-58.
5. Heath P, Ramsay M. Haemophilus influenzae type b vaccine - booster campaign. British Medical Journal 2003; 326: 1158-1159.
6. Ramsay M, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. Journal of Infectious Diseases 2003; 188: 481-485.
7. Trotter CL, et al. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003; 361 1523-1524.
8. Murphy T, et al. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatrics 1993; 122: 517-523.
9. Barbour M, et al. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. Journal of Infectious Diseases 1995; 171: 93-98.
10. Takala A, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. Journal of Infectious Diseases 1991; 164: 982-986.
11. Mohle-Boetani J, et al. Carrige of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatric Infectious Disease Journal 1993; 12: 589-593.
12. McVernon J, et al. Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiology and Infection 2004; 132: 765-767.
13. Michaels R, Norden C. Pharyngeal colonization with Haemophilus influenzae type b: A longitudinal study of families with a child with meningitis or epiglottitis due to H influenzae type b. Journal of Infectious Diseases 1977; 136: 222-228.
14. Hall D, et al. Pharyngeal carriage and acquisition of anticapsular antibody to Haemophilus influenzae type b in a high-risk population in southwestern Alaska. American Journal of Epidemiology 1987; 126: 1190-1197.
15. Fothergill L, Wright J. Influenzal meningitis. The relation of age incidence to the bactericidal power of blood against the causal organism. Journal of Immunology 1933; 24: 273-284.
16. Anderson P, et al. Antibody to polyribophosphate of Haemophilus influenzae type b in infants and children: Effect of imunization with polyribophosphate. Journal of Infectious Diseases 1977; 136 (Suppl.): S57-S62.
17. Kayhty H, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. Journal of Infectious Diseases 1983; 147: 1100.
18. Halloran M, et al. Population biology, evolution, and immunology of vaccination and vaccination programs. American Journal of Medical Science 1998; 315: 76-86.
19. Michaels R, et al. Factors affecting pharyngeal Haemophilus influenzae type b colonization rates in children. Journal of Clinical Microbiology 1976; 4: 413-417.
20. Howard A, Dunkin K, Millar G. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae in healthy children. Epidemiology and infection 1989; 100: 193-203.
21. van Alphen L, et al. Antibodies to Haemophilus influenzae type b polysaccharide affect bacterial adherence and multiplication. Infection and Immunity 1996; 64: 995-1001.
22. Kauppi-Korkeila M, et al. Mechanism of antibody- mediated 'redilction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. Journal of Infectious Disease 1996; 174: 1337- 1340.
23. Fernandez J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination: Correlation with serum anti-capsular IgG concentration. Journal of Infectious Diseases 2000; 182: 1553-1556.
24. Goldblatt D, et al. Immunological response to conjugate vaccines in infants: A follow up study. British Medical Journal 1998; 316: 1570-1571.
25. Anderson RM, May R. Infectious Disease of Humans: Oxford University Press, 1991.
26. Murphy T, et al. Pharyngeal colonization with Haemophilus influenzae type b in children in a day care center without invasive disease. Journal of Paediatrics 1985; 106: 712-716.
27. Turk D. Naso-pharyngeal carriage of Haemophilus influenzae type b. Journal of Hygiene 1963; 61: 247-256.
28. Makela P, et al. Polysaccharide vaccines of Group A Neisseria meningitidis and Haemophilus influenzae type b: A field trial in Finland. Journal of Infectious Diseases 1977; 136 (Suppl): S43-S50.
29. Robbins J, et al. Prevention of systemic infectrions, especially meningitis, caused by Haemophilus influenzae type b. Journal of the American Medical Association 1996; 276: 1181-1185.
30. Kayhty H, et al. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory. Pediatrics 1984; 74: 857-865.
31. Madore D, et al. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15-23 months. Pediatrics 1990; 86: 527-534.
32. Rothstein E, et al. Response of 7-15 month old infants to sequential immunization with Haemophilus influenzae type b CRM197 conjugate and polysaccharide vaccines. American Journal of Diseases of Children 1991; 145: 898-900.
33. Barbour M, et al. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM 197 (HbOC) conjugate vaccine. Pediatric Infectious Disease Journal 1993; 12: 478-484.
34. Goldblatt D, et al. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. Journal of Infectious Diseases 1998; 177: 1112-1115.
35. Scheifele D, et al. Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. Journal of Paediatrics 1999; 135: 240-245.
36. Makela P, et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22 287-292.
37. Bell F, et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine 1998; 16: 637-642.
38. Leino T, et al. Indirect protection obtained by Haemophilus influenzae type b vaccination: Analysis in a structured population model. Epidemiology and Infection 2004; 132: 959-966.
39. Eskola J, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354: 2063-2068.
40. Poolman J, et al. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 2001; 19: 2280-2285.
41. Singleton R, et al. Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: The impact of persistent oropharyngeal carriage. Journal of Paediatrics 2000; 137: 313-320.
42. Smith A. Pathogenesis of Haemophilus influenzae meningitis. Pediatric Infectious Disease Journal 1987; 6: 783-786.
43. Coen P, et al. Mathematical models of Haemophilus influenzae type b. Epidemiology and Infection 1998; 120: 281-295.
44. Rushdy A, et al. Infant Hib vaccination and herd immunity. Journal of Paediatrics 1999; 134: 253-254.
45. McVernon J, et al. Trends in Haemophilus influenzae type b infections in adults in England and Wales: Surveillance study. British Medical Journal 2004; 329: 655-658.
46. Leino T, et al. Haemophilus influenzae type b and cross-reactive antigens in natural Hib infection dynamics: Modelling in two populations. Epidemiology and Infection 2002; 129: 73-83.
47. Auranen K, et al. Modelling transmission, immunity and disease of Haemophilus influenzae type b in a structured population. Epidemiology and Infection 2004; 132: 947-957.
48. Ounsted C. Ecology of Haemophilus influenzae meningitis. Lancet 1951; 257: 800-801.
49. Trotter C, Gay N, Edmunds W. Dynamic models of meningococcal carriage, disease and the impact of serogroup C conjugate vaccination. American Journal of Epidemiology 2005; 162 89-100.
50. Myerowitz R, Norden C, Demchak T. Significance of noncapsular antigens in protection against experimental Haemphilus influenzae type b disease; cross-reactivity. Infection and Immunity 1978; 21: 619-626.
51. Robbins J, et al. Quantitative measurement of 'natural' and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatric Research 1973; 7: 103-110.
52. Coen P, Heath P, Garnett G. The Hib immunization programme in the Oxford-region: An analysis of the impact of vaccine administration on the incidence of disease. Epidemiology and Infection 1999; 123 389-402.
53. Insel R, Anderson P. Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type b. Journal of Immunology 1982; 128: 1267-1270.
54. Bolker B, Grenfell B. Impact of vaccination on the spatial correlation and persistence of measles dynamics. Proceedings of the National Academy of Sciences 1996; 93: 12648-12653.
55. Boisvert P. Familial epidemiology of Hemophilus influenzae, type b, infections. American Journal of Diseases of Children 1948; 77: 427-428.
56. Glode M, et al. Epiglottitis in adults: Association with Haemophilus influenzae type b colonization and disease in children. Pediatric Infectious Diseases Journal 1984; 3: 548-551.
57. Trotter C, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2001; 364 365-367.